These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31385309)

  • 1. Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
    Pulsoni A; Della Starza I; Cappelli LV; Tosti ME; Annechini G; Cavalli M; De Novi LA; D'Elia GM; Grapulin L; Guarini A; Del Giudice I; Foà R
    Br J Haematol; 2020 Jan; 188(2):249-258. PubMed ID: 31385309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
    Cavalli M; De Novi LA; Della Starza I; Cappelli LV; Nunes V; Pulsoni A; Del Giudice I; Guarini A; Foà R
    Br J Haematol; 2017 May; 177(4):588-596. PubMed ID: 28419517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial.
    Pulsoni A; Ferrero S; Tosti ME; Luminari S; Dondi A; Cavallo F; Merli F; Liberati AM; Cenfra N; Renzi D; Zanni M; Boccomini C; Ferreri AJM; Rattotti S; Zilioli VR; Bolis SA; Bernuzzi P; Musuraca G; Gaidano G; Perrone T; Stelitano C; Tucci A; Corradini P; Bigliardi S; Re F; Cencini E; Mannarella C; Mannina D; Celli M; Tani M; Annechini G; Assanto GM; Grapulin L; Guarini A; Cavalli M; De Novi LA; Bomben R; Ciabatti E; Genuardi E; Drandi D; Della Starza I; Arcaini L; Ricardi U; Gattei V; Galimberti S; Ladetto M; Foà R; Del Giudice I
    Lancet Haematol; 2024 Jul; 11(7):e499-e509. PubMed ID: 38937025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
    Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M
    Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
    Drandi D; Ferrero S; Ladetto M
    Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
    Ladetto M; Lobetti-Bodoni C; Mantoan B; Ceccarelli M; Boccomini C; Genuardi E; Chiappella A; Baldini L; Rossi G; Pulsoni A; Di Raimondo F; Rigacci L; Pinto A; Galimberti S; Bari A; Rota-Scalabrini D; Ferrari A; Zaja F; Gallamini A; Specchia G; Musto P; Rossi FG; Gamba E; Evangelista A; Vitolo U;
    Blood; 2013 Nov; 122(23):3759-66. PubMed ID: 24085766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Leuk Lymphoma; 2015; 56(8):2350-6. PubMed ID: 25426666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
    Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.
    Delfau-Larue MH; Boulland ML; Beldi-Ferchiou A; Feugier P; Maisonneuve H; Casasnovas RO; Lemonnier F; Pica GM; Houot R; Ysebaert L; Tilly H; Eisenmann JC; Le Gouill S; Ribrag V; Godmer P; Glaisner S; Cartron G; Xerri L; Salles GA; Fest T; Morschhauser F
    Blood Adv; 2020 Aug; 4(14):3217-3223. PubMed ID: 32673385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
    Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
    Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
    Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.
    Galimberti S; Ciabatti E; Ercolano G; Grassi S; Guerrini F; Cecconi N; Rousseau M; Cervetti G; Mazziotta F; Iovino L; Falzetti F; Falcinelli F; Bosi A; Rigacci L; Kovalchuk S; Vallisa D; Macchia L; Ciancia E; Petrini M
    Front Pharmacol; 2017; 8():413. PubMed ID: 28706485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response monitoring in follicular lymphoma by synchronous evaluation of minimal residual disease and diffusion-weighted MRI.
    Meleshko AN; Kharuzhyk SA; Piatrouskaya NA
    Exp Oncol; 2015 Dec; 37(4):295-7. PubMed ID: 26710844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
    Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
    Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.
    Hirt C; Schüler F; Dölken G
    Semin Cancer Biol; 2003 Jun; 13(3):223-31. PubMed ID: 12959353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
    Cencini E; Puccini B; Rigacci L; Fabbri A; Kovalchuk S; Mannelli L; Benelli G; Carfagno T; Simontacchi G; Bocchia M; Bosi A
    Leuk Lymphoma; 2018 Jun; 59(6):1420-1426. PubMed ID: 28994343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.